Skip to main content
Top
Published in: Internal and Emergency Medicine 4/2021

Open Access 01-06-2021 | IgA Vasculitis | IM - REVIEW

Diagnosis and management of leukocytoclastic vasculitis

Authors: Paolo Fraticelli, Devis Benfaremo, Armando Gabrielli

Published in: Internal and Emergency Medicine | Issue 4/2021

Login to get access

Abstract

Leukocytoclastic vasculitis (LCV) is a histopathologic description of a common form of small vessel vasculitis (SVV), that can be found in various types of vasculitis affecting the skin and internal organs. The leading clinical presentation of LCV is palpable purpura and the diagnosis relies on histopathological examination, in which the inflammatory infiltrate is composed of neutrophils with fibrinoid necrosis and disintegration of nuclei into fragments (“leukocytoclasia”). Several medications can cause LCV, as well as infections, or malignancy. Among systemic diseases, the most frequently associated with LCV are ANCA-associated vasculitides, connective tissue diseases, cryoglobulinemic vasculitis, IgA vasculitis (formerly known as Henoch–Schonlein purpura) and hypocomplementemic urticarial vasculitis (HUV). When LCV is suspected, an extensive workout is usually necessary to determine whether the process is skin-limited, or expression of a systemic vasculitis or disease. A comprehensive history and detailed physical examination must be performed; platelet count, renal function and urinalysis, serological tests for hepatitis B and C viruses, autoantibodies (anti-nuclear antibodies and anti-neutrophil cytoplasmic antibodies), complement fractions and IgA staining in biopsy specimens are part of the usual workout of LCV. The treatment is mainly focused on symptom management, based on rest (avoiding standing or walking), low dose corticosteroids, colchicine or different unproven therapies, if skin-limited. When a medication is the cause, the prognosis is favorable and the discontinuation of the culprit drug is usually resolutive. Conversely, when a systemic vasculitis is the cause of LCV, higher doses of corticosteroids or immunosuppressive agents are required, according to the severity of organ involvement and the underlying associated disease.
Literature
1.
go back to reference Caproni M, Verdelli A (2019) An update on the nomenclature for cutaneous vasculitis. Curr Opin Rheumatol 31(1):46–52PubMedCrossRef Caproni M, Verdelli A (2019) An update on the nomenclature for cutaneous vasculitis. Curr Opin Rheumatol 31(1):46–52PubMedCrossRef
2.
go back to reference Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F et al (2013) 2012 revised International Chapel hill consensus conference nomenclature of vasculitides. Arthritis Rheum 65(1):1–11PubMedCrossRef Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F et al (2013) 2012 revised International Chapel hill consensus conference nomenclature of vasculitides. Arthritis Rheum 65(1):1–11PubMedCrossRef
3.
go back to reference Sunderkötter CH, Zelger B, Chen KR, Requena L, Piette W, Carlson JA et al (2018) Nomenclature of cutaneous vasculitis: dermatologic addendum to the 2012 revised International Chapel Hill consensus conference nomenclature of vasculitides. Arthritis Rheumatol 70(2):171–184PubMedCrossRef Sunderkötter CH, Zelger B, Chen KR, Requena L, Piette W, Carlson JA et al (2018) Nomenclature of cutaneous vasculitis: dermatologic addendum to the 2012 revised International Chapel Hill consensus conference nomenclature of vasculitides. Arthritis Rheumatol 70(2):171–184PubMedCrossRef
4.
5.
go back to reference Watts RA, Jolliffe VA, Grattan CEH, Elliott J, Lockwood M, Scott DGI. Cutaneous vasculitis in a defined population-Clinical and epidemiological associations. Vol. 25, Journal of Rheumatology. Department of Rheumatology, Ipswich Hospital, UK. FAU-Jolliffe, V A; 1998. p. 920–4. Watts RA, Jolliffe VA, Grattan CEH, Elliott J, Lockwood M, Scott DGI. Cutaneous vasculitis in a defined population-Clinical and epidemiological associations. Vol. 25, Journal of Rheumatology. Department of Rheumatology, Ipswich Hospital, UK. FAU-Jolliffe, V A; 1998. p. 920–4.
6.
go back to reference Haugeberg G, Bie R, Bendvold A, Storm Larsen A, Johnsen V (1998) Primary vasculitis in a Norwegian community hospital: a retrospective study. Clin Rheumatol 17(5):364–368PubMedCrossRef Haugeberg G, Bie R, Bendvold A, Storm Larsen A, Johnsen V (1998) Primary vasculitis in a Norwegian community hospital: a retrospective study. Clin Rheumatol 17(5):364–368PubMedCrossRef
7.
go back to reference Garcia-Porrua C, Gonzalez-Gay MA (1999) Comparative clinical and epidemiological study of hypersensitivity vasculitis versus Henoch-Schonlein purpura in adults. Semin Arthritis Rheum 28(6):404–412PubMedCrossRef Garcia-Porrua C, Gonzalez-Gay MA (1999) Comparative clinical and epidemiological study of hypersensitivity vasculitis versus Henoch-Schonlein purpura in adults. Semin Arthritis Rheum 28(6):404–412PubMedCrossRef
8.
go back to reference Arora A, Wetter DA, Gonzalez-Santiago TM, Davis MDP, Lohse CM (2014) Incidence of leukocytoclastic vasculitis, 1996 to 2010: a population-based study in olmsted county, minnesota. Mayo Clin Proc 89(11):1515–1524PubMedPubMedCentralCrossRef Arora A, Wetter DA, Gonzalez-Santiago TM, Davis MDP, Lohse CM (2014) Incidence of leukocytoclastic vasculitis, 1996 to 2010: a population-based study in olmsted county, minnesota. Mayo Clin Proc 89(11):1515–1524PubMedPubMedCentralCrossRef
9.
go back to reference Blanco R, Martínez-Taboada VM, Rodríguez-Valverde V, García-Fuentes M (1998) Cutaneous vasculitis in children and adults: Associated diseases and etiologic factors in 303 patients. Medicine (Baltimore) 77(6):403–418 Blanco R, Martínez-Taboada VM, Rodríguez-Valverde V, García-Fuentes M (1998) Cutaneous vasculitis in children and adults: Associated diseases and etiologic factors in 303 patients. Medicine (Baltimore) 77(6):403–418
10.
go back to reference Bouiller K, Audia S, Devilliers H, Collet E, Aubriot MH, Leguy-Seguin V et al (2016) Etiologies and prognostic factors of leukocytoclastic vasculitis with skin involvement: a retrospective study in 112 patients. Med (United States) 95(28):e4238 Bouiller K, Audia S, Devilliers H, Collet E, Aubriot MH, Leguy-Seguin V et al (2016) Etiologies and prognostic factors of leukocytoclastic vasculitis with skin involvement: a retrospective study in 112 patients. Med (United States) 95(28):e4238
11.
go back to reference Pastuszczak M, Celińska-Löwenhoff M, Sułowicz J, Wojas-Pelc A, Musiał J (2017) Clinical study on single-organ cutaneous small vessels vasculitis (SoCSVV). Med (United States) 96(12):e6376 Pastuszczak M, Celińska-Löwenhoff M, Sułowicz J, Wojas-Pelc A, Musiał J (2017) Clinical study on single-organ cutaneous small vessels vasculitis (SoCSVV). Med (United States) 96(12):e6376
12.
go back to reference Loricera J, Blanco R, Ortiz-sanjuán F, Hernández JL, Pina T, González-vela MC et al (2014) Single-organ cutaneous small-vessel vasculitis according to the 2012 revised International Chapel Hill Consensus Conference Nomenclature Of Vasculitides: a study of 60 patients from a series of 766 cutaneous vasculitis cases. Rheumatol (United Kingdom) 54(1):77–82 Loricera J, Blanco R, Ortiz-sanjuán F, Hernández JL, Pina T, González-vela MC et al (2014) Single-organ cutaneous small-vessel vasculitis according to the 2012 revised International Chapel Hill Consensus Conference Nomenclature Of Vasculitides: a study of 60 patients from a series of 766 cutaneous vasculitis cases. Rheumatol (United Kingdom) 54(1):77–82
13.
go back to reference Gyselbrecht L, De Keyser F, Ongenae K, Naeyaert JM, Praet M, Veys EM. Etiological factors and underlying conditions in patients with leucocytoclastic vasculitis. Vol. 14, Clinical and Experimental Rheumatology. Department of Rheumatology, University Hospital, Ghent, Belgium. FAU-De Keyser, F; 1996. p. 665–8. Gyselbrecht L, De Keyser F, Ongenae K, Naeyaert JM, Praet M, Veys EM. Etiological factors and underlying conditions in patients with leucocytoclastic vasculitis. Vol. 14, Clinical and Experimental Rheumatology. Department of Rheumatology, University Hospital, Ghent, Belgium. FAU-De Keyser, F; 1996. p. 665–8.
14.
go back to reference Sais G, Vidaller A, Jucglà A, Servitje O, Condom E, Peyrí J (1998) Prognostic factors in leukocytoclastic vasculitis: a clinicopathologic study of 160 patients. Arch Dermatol 134(3):309–315PubMedCrossRef Sais G, Vidaller A, Jucglà A, Servitje O, Condom E, Peyrí J (1998) Prognostic factors in leukocytoclastic vasculitis: a clinicopathologic study of 160 patients. Arch Dermatol 134(3):309–315PubMedCrossRef
15.
16.
go back to reference Mackel SE, Jordon RE (1982) Leukocytoclastic vasculitis: a Cutaneous expression of immune complex disease. Arch Dermatol 118(5):296–301PubMedCrossRef Mackel SE, Jordon RE (1982) Leukocytoclastic vasculitis: a Cutaneous expression of immune complex disease. Arch Dermatol 118(5):296–301PubMedCrossRef
17.
go back to reference He X, Yu C, Zhao P, Ding Y, Liang X, Zhao Y et al (2013) The genetics of Henoch-Schönlein purpura: a systematic review and meta-analysis. Rheumatol Int 33(6):1387–1395PubMedCrossRef He X, Yu C, Zhao P, Ding Y, Liang X, Zhao Y et al (2013) The genetics of Henoch-Schönlein purpura: a systematic review and meta-analysis. Rheumatol Int 33(6):1387–1395PubMedCrossRef
18.
go back to reference Terrier B, Cacoub P (2013) Cryoglobulinemia vasculitis: an update. Curr Opin Rheumatol 25(1):10–18PubMedCrossRef Terrier B, Cacoub P (2013) Cryoglobulinemia vasculitis: an update. Curr Opin Rheumatol 25(1):10–18PubMedCrossRef
19.
go back to reference Galli M, Oreni L, Saccardo F, Castelnovo L, Filippini D, Marson P, et al HCV-unrelated cryoglobulinaemic vasculitis: the results of a prospective observational study by the Italian Group for the Study of Cryoglobulinaemias (GISC). Vol. 35, Clinical and Experimental Rheumatology. Clinica delle Malattie Infettive, L. Sacco Department of Biomedical and Clinical Sciences, University of Milan, Italy. massimo.galli@unimi.it. FAU-Oreni, Letizia; 2017. p. 67–76. Galli M, Oreni L, Saccardo F, Castelnovo L, Filippini D, Marson P, et al HCV-unrelated cryoglobulinaemic vasculitis: the results of a prospective observational study by the Italian Group for the Study of Cryoglobulinaemias (GISC). Vol. 35, Clinical and Experimental Rheumatology. Clinica delle Malattie Infettive, L. Sacco Department of Biomedical and Clinical Sciences, University of Milan, Italy. massimo.galli@unimi.it. FAU-Oreni, Letizia; 2017. p. 67–76.
20.
go back to reference Boom BW, Mommaas AM, Vermeer BJ (1992) Presence and interpretation of vascular immune deposits in human skin: the value of direct immunofluorescence. J Dermatol Sci 3(1):26–34PubMedCrossRef Boom BW, Mommaas AM, Vermeer BJ (1992) Presence and interpretation of vascular immune deposits in human skin: the value of direct immunofluorescence. J Dermatol Sci 3(1):26–34PubMedCrossRef
21.
go back to reference Schroeter AL, Conn DL, Jordon RE (1976) Immunoglobulin and complement deposition in skin of rheumatoid arthritis and systemic lupus erythematosus patients. Ann Rheum Dis 35(4):321–326PubMedPubMedCentralCrossRef Schroeter AL, Conn DL, Jordon RE (1976) Immunoglobulin and complement deposition in skin of rheumatoid arthritis and systemic lupus erythematosus patients. Ann Rheum Dis 35(4):321–326PubMedPubMedCentralCrossRef
22.
go back to reference Sanchez NP, Van Hale HM, Daniel Su WP (1985) Clinical and histopathologic spectrum of necrotizing vasculitis: report of findings in 101 cases. Arch Dermatol 121(2):220–224PubMedCrossRef Sanchez NP, Van Hale HM, Daniel Su WP (1985) Clinical and histopathologic spectrum of necrotizing vasculitis: report of findings in 101 cases. Arch Dermatol 121(2):220–224PubMedCrossRef
23.
go back to reference Chen KR, Toyohara A, Suzuki A, Miyakawa S (2002) Clinical and histopathological spectrum of cutaneous vasculitis in rheumatoid arthritis. Br J Dermatol 147(5):905–913PubMedCrossRef Chen KR, Toyohara A, Suzuki A, Miyakawa S (2002) Clinical and histopathological spectrum of cutaneous vasculitis in rheumatoid arthritis. Br J Dermatol 147(5):905–913PubMedCrossRef
24.
go back to reference Ramos-Casals M, Nardi N, Lagrutta M, Brito-Zerón P, Bové A, Delgado G et al (2006) Vasculitis in systemic lupus erythematosus: prevalence and clinical characteristics in 670 patients. Medicine (Baltimore) 85(2):95–104CrossRef Ramos-Casals M, Nardi N, Lagrutta M, Brito-Zerón P, Bové A, Delgado G et al (2006) Vasculitis in systemic lupus erythematosus: prevalence and clinical characteristics in 670 patients. Medicine (Baltimore) 85(2):95–104CrossRef
25.
go back to reference Barile-Fabris L, Hernández-Cabrera MF, Barragan-Garfias JA (2014) Vasculitis in systemic lupus erythematosus. Curr Rheumatol Rep 16(9):440PubMedCrossRef Barile-Fabris L, Hernández-Cabrera MF, Barragan-Garfias JA (2014) Vasculitis in systemic lupus erythematosus. Curr Rheumatol Rep 16(9):440PubMedCrossRef
26.
go back to reference Finder KA, McCollough ML, Dixon SL, Majka AJ, Jaremko W (1990) Hypergammaglobulinemic purpura of Waldenström. J Am Acad Dermatol 23(4):669–676PubMedCrossRef Finder KA, McCollough ML, Dixon SL, Majka AJ, Jaremko W (1990) Hypergammaglobulinemic purpura of Waldenström. J Am Acad Dermatol 23(4):669–676PubMedCrossRef
27.
go back to reference Aractingi S, Cadranel J, Milleron B, Saiag P, Malepar MJ, Dubertret L (1993) Sarcoidosis associated with leucocytoclastic vasculitis: a case report and review of the literature. Dermatology 187(1):50–53PubMedCrossRef Aractingi S, Cadranel J, Milleron B, Saiag P, Malepar MJ, Dubertret L (1993) Sarcoidosis associated with leucocytoclastic vasculitis: a case report and review of the literature. Dermatology 187(1):50–53PubMedCrossRef
28.
go back to reference R. Blanco MAG-GCG-PMJG-P (1998) Cutaneous vasculitis: an unusual presentation of sarcoidosis in adulthood. Scand J Rheumatol. 27(1):80–2. R. Blanco MAG-GCG-PMJG-P (1998) Cutaneous vasculitis: an unusual presentation of sarcoidosis in adulthood. Scand J Rheumatol. 27(1):80–2.
29.
go back to reference Ortiz-Sanjuán F, Blanco R, Hernández JL, Pina T, González-Vela MC, Fernández-Llaca H et al (2014) Drug-associated cutaneous vasculitis: study of 239 patients from a single referral center. J Rheumatol 41(11):2201–2207PubMedCrossRef Ortiz-Sanjuán F, Blanco R, Hernández JL, Pina T, González-Vela MC, Fernández-Llaca H et al (2014) Drug-associated cutaneous vasculitis: study of 239 patients from a single referral center. J Rheumatol 41(11):2201–2207PubMedCrossRef
30.
go back to reference García-Porrúa C, González-Gay MA, López-Lázaro L (1999) Drug associated cutaneous vasculitis in adults in northwestern Spain. Vol. 26, Journal of Rheumatology. Division of Rheumatology, Hospital Xeral-Calde, Lugo, Spain. FAU-Gonzalez-Gay, M A, p. 1942–4. García-Porrúa C, González-Gay MA, López-Lázaro L (1999) Drug associated cutaneous vasculitis in adults in northwestern Spain. Vol. 26, Journal of Rheumatology. Division of Rheumatology, Hospital Xeral-Calde, Lugo, Spain. FAU-Gonzalez-Gay, M A, p. 1942–4.
31.
go back to reference Grau RG (2015) Drug-induced vasculitis: new insights and a changing lineup of suspects. Curr Rheumatol Rep 17(12):71PubMedCrossRef Grau RG (2015) Drug-induced vasculitis: new insights and a changing lineup of suspects. Curr Rheumatol Rep 17(12):71PubMedCrossRef
32.
go back to reference Sokumbi O, Wetter DA, Makol A, Warrington KJ (2012) Vasculitis associated with tumor Necrosis factor-α. Inhibitors Mayo Clin Proc 87(8):739–745PubMedCrossRef Sokumbi O, Wetter DA, Makol A, Warrington KJ (2012) Vasculitis associated with tumor Necrosis factor-α. Inhibitors Mayo Clin Proc 87(8):739–745PubMedCrossRef
33.
go back to reference Kandula P, Kouides PA (2006) Rituximab-induced leukocytoclastic vasculitis: a case report. Arch Dermatol 142(2):246–247PubMedCrossRef Kandula P, Kouides PA (2006) Rituximab-induced leukocytoclastic vasculitis: a case report. Arch Dermatol 142(2):246–247PubMedCrossRef
34.
go back to reference Sakaue S, Sumitomo S, Kubo K, Fujio K, Yamamoto K (2014) Tocilizumab-induced leucocytoclastic vasculitis in a patient with rheumatoid arthritis. Rheumatology 53(8):1529–1530PubMedCrossRef Sakaue S, Sumitomo S, Kubo K, Fujio K, Yamamoto K (2014) Tocilizumab-induced leucocytoclastic vasculitis in a patient with rheumatoid arthritis. Rheumatology 53(8):1529–1530PubMedCrossRef
35.
go back to reference Gonen KA, Erfan G, Oznur M, Erdogan C (2014) The first case of Henoch-Schönlein purpura associated with rosuvastatin: colonic involvement coexisting with small intestine. BMJ Case Rep 2014:bcr2013202644PubMedPubMedCentralCrossRef Gonen KA, Erfan G, Oznur M, Erdogan C (2014) The first case of Henoch-Schönlein purpura associated with rosuvastatin: colonic involvement coexisting with small intestine. BMJ Case Rep 2014:bcr2013202644PubMedPubMedCentralCrossRef
36.
go back to reference Tomelleri A, Campochiaro C, De Luca G, Cavalli G, Dagna L (2018) Anti-PD1 therapy-associated cutaneous leucocytoclastic vasculitis: A case series. Eur J Intern Med 1(57):e11–e12CrossRef Tomelleri A, Campochiaro C, De Luca G, Cavalli G, Dagna L (2018) Anti-PD1 therapy-associated cutaneous leucocytoclastic vasculitis: A case series. Eur J Intern Med 1(57):e11–e12CrossRef
37.
go back to reference Greco F, Sorge A, Salvo V, Sorge G (2007) Cutaneous vasculitis associated with mycoplasma pneumoniae infection: case report and literature review. Clin Pediatr (Phila) 46(5):451–453CrossRef Greco F, Sorge A, Salvo V, Sorge G (2007) Cutaneous vasculitis associated with mycoplasma pneumoniae infection: case report and literature review. Clin Pediatr (Phila) 46(5):451–453CrossRef
38.
go back to reference Kim HM, Park YB, Maeng HY, Lee SK (2006) Cutaneous leukocytoclastic vasculitis with cervical tuberculous lymphadenitis: a case report and literature review. Rheumatol Int 26(12):1154–1157PubMedCrossRef Kim HM, Park YB, Maeng HY, Lee SK (2006) Cutaneous leukocytoclastic vasculitis with cervical tuberculous lymphadenitis: a case report and literature review. Rheumatol Int 26(12):1154–1157PubMedCrossRef
39.
go back to reference Belizna CC, Hamidou MA, Levesque H, Guillevin L, Shoenfeld Y (2009) Infection and vasculitis. Rheumatology 48(5):475–482PubMedCrossRef Belizna CC, Hamidou MA, Levesque H, Guillevin L, Shoenfeld Y (2009) Infection and vasculitis. Rheumatology 48(5):475–482PubMedCrossRef
40.
go back to reference Loricera J, Calvo-Río V, Ortiz-Sanjuán F, González-López MA, Fernández-Llaca H, Rueda-Gotor J et al (2013) The spectrum of paraneoplastic cutaneous vasculitis in a defined population: incidence and clinical features. Med (United States) 92(6):331–343 Loricera J, Calvo-Río V, Ortiz-Sanjuán F, González-López MA, Fernández-Llaca H, Rueda-Gotor J et al (2013) The spectrum of paraneoplastic cutaneous vasculitis in a defined population: incidence and clinical features. Med (United States) 92(6):331–343
41.
go back to reference Podjasek JO, Wetter DA, Pittelkow MR, Wada DA (2012) Cutaneous small-vessel vasculitis associated with solid organ malignancies: the Mayo Clinic experience, 1996 to 2009. J Am Acad Dermatol 66(2):e55-65PubMedCrossRef Podjasek JO, Wetter DA, Pittelkow MR, Wada DA (2012) Cutaneous small-vessel vasculitis associated with solid organ malignancies: the Mayo Clinic experience, 1996 to 2009. J Am Acad Dermatol 66(2):e55-65PubMedCrossRef
42.
go back to reference Brouet J-C, Clauvel J-P, Danon F, Klein M, Seligmann M (1974) Biologic and clinical significance of cryoglobulins: a report of 86 cases. Am J Med 57(5):775–788PubMedCrossRef Brouet J-C, Clauvel J-P, Danon F, Klein M, Seligmann M (1974) Biologic and clinical significance of cryoglobulins: a report of 86 cases. Am J Med 57(5):775–788PubMedCrossRef
43.
go back to reference Takatu CM, Heringer APR, Aoki V, Valente NYS, de Faria Sanchez PC, de Carvalho JF et al (2017) Clinicopathologic correlation of 282 leukocytoclastic vasculitis cases in a tertiary hospital: a focus on direct immunofluorescence findings at the blood vessel wall. Immunol Res 65(1):395–401PubMedCrossRef Takatu CM, Heringer APR, Aoki V, Valente NYS, de Faria Sanchez PC, de Carvalho JF et al (2017) Clinicopathologic correlation of 282 leukocytoclastic vasculitis cases in a tertiary hospital: a focus on direct immunofluorescence findings at the blood vessel wall. Immunol Res 65(1):395–401PubMedCrossRef
44.
go back to reference Sais G, Vidaller A, Jucglà A, Gallardo F, Peyrí J (1995) Colchicine in the treatment of cutaneous leukocytoclastic vasculitis: results of a prospective randomized controlled trial. Arch Dermatol 131(12):1399–1402PubMedCrossRef Sais G, Vidaller A, Jucglà A, Gallardo F, Peyrí J (1995) Colchicine in the treatment of cutaneous leukocytoclastic vasculitis: results of a prospective randomized controlled trial. Arch Dermatol 131(12):1399–1402PubMedCrossRef
45.
go back to reference Fredenberg MF, Malkinson FD (1987) Sulfone therapy in the treatment of leukocytoclastic vasculitis: report of three cases. J Am Acad Dermatol 16(4):772–778PubMedCrossRef Fredenberg MF, Malkinson FD (1987) Sulfone therapy in the treatment of leukocytoclastic vasculitis: report of three cases. J Am Acad Dermatol 16(4):772–778PubMedCrossRef
46.
go back to reference Lopez LR, Davis KC, Kohler PF, Schocket AL (1984) The hypocomplementemic urticarial-vasculitis syndrome: therapeutic response to hydroxychloroquine. J Allergy Clin Immunol. 73(5):600–603PubMedCrossRef Lopez LR, Davis KC, Kohler PF, Schocket AL (1984) The hypocomplementemic urticarial-vasculitis syndrome: therapeutic response to hydroxychloroquine. J Allergy Clin Immunol. 73(5):600–603PubMedCrossRef
47.
go back to reference Callen JP, Spencer LV, Burruss JB, Holtman J (1991) Azathioprine: an effective, Corticosteroid-sparing therapy for patients with Recalcitrant Cutaneous Lupus erythematosus or with recalcitrant cutaneous leukocytoclastic vasculitis. Arch Dermatol 127(4):515–522PubMedCrossRef Callen JP, Spencer LV, Burruss JB, Holtman J (1991) Azathioprine: an effective, Corticosteroid-sparing therapy for patients with Recalcitrant Cutaneous Lupus erythematosus or with recalcitrant cutaneous leukocytoclastic vasculitis. Arch Dermatol 127(4):515–522PubMedCrossRef
48.
go back to reference Jorizzo JL, White WL, Wise CM, Zanoffi MD, Sherertz EF (1991) Low-dose weekly methotrexate for unusual neutrophilic vascular reactions: cutaneous polyarteritis nodosa and Behçeťs disease. J Am Acad Dermatol. 24(6):973–978PubMedCrossRef Jorizzo JL, White WL, Wise CM, Zanoffi MD, Sherertz EF (1991) Low-dose weekly methotrexate for unusual neutrophilic vascular reactions: cutaneous polyarteritis nodosa and Behçeťs disease. J Am Acad Dermatol. 24(6):973–978PubMedCrossRef
49.
go back to reference Haeberle MT, Adams WB, Callen JP (2012) Treatment of severe cutaneous small-vessel vasculitis with mycophenolate mofetil. Arch Dermatol 148(8):887–888PubMedCrossRef Haeberle MT, Adams WB, Callen JP (2012) Treatment of severe cutaneous small-vessel vasculitis with mycophenolate mofetil. Arch Dermatol 148(8):887–888PubMedCrossRef
50.
go back to reference Audemard-Verger A, Terrier B, Dechartres A, Chanal J, Amoura Z, Le Gouellec N et al (2017) Characteristics and management of IgA vasculitis (Henoch-Schönlein) in adults: data from 260 patients included in a French multicenter retrospective survey. Arthritis Rheumatol 69(9):1862–1870PubMedCrossRef Audemard-Verger A, Terrier B, Dechartres A, Chanal J, Amoura Z, Le Gouellec N et al (2017) Characteristics and management of IgA vasculitis (Henoch-Schönlein) in adults: data from 260 patients included in a French multicenter retrospective survey. Arthritis Rheumatol 69(9):1862–1870PubMedCrossRef
51.
go back to reference Jachiet M, Flageul B, Deroux A, Le Quellec A, Maurier F, Cordoliani F et al (2015) The clinical spectrum and therapeutic management of hypocomplementemic urticarial vasculitis: data from a french nationwide study of fifty-seven patients. Arthritis Rheumatol 67(2):527–534PubMedCrossRef Jachiet M, Flageul B, Deroux A, Le Quellec A, Maurier F, Cordoliani F et al (2015) The clinical spectrum and therapeutic management of hypocomplementemic urticarial vasculitis: data from a french nationwide study of fifty-seven patients. Arthritis Rheumatol 67(2):527–534PubMedCrossRef
52.
go back to reference Galli M, Monti G, Marson P, Scaini P, Pietrogrande M, Candela M et al (2019) Recommendations for managing the manifestations of severe and life-threatening mixed cryoglobulinemia syndrome. Autoimmun Rev 18(8):778–785PubMedCrossRef Galli M, Monti G, Marson P, Scaini P, Pietrogrande M, Candela M et al (2019) Recommendations for managing the manifestations of severe and life-threatening mixed cryoglobulinemia syndrome. Autoimmun Rev 18(8):778–785PubMedCrossRef
53.
go back to reference McClure M, Gopaluni S, Jayne D, Jones R (2018) B cell therapy in ANCA-associated vasculitis: current and emerging treatment options. Nat Rev Rheumatol 14(10):580–591PubMedCrossRef McClure M, Gopaluni S, Jayne D, Jones R (2018) B cell therapy in ANCA-associated vasculitis: current and emerging treatment options. Nat Rev Rheumatol 14(10):580–591PubMedCrossRef
54.
go back to reference De Vita S, Quartuccio L, Isola M, Mazzaro C, Scaini P, Lenzi M et al (2012) A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis. Arthritis Rheum 64(3):843–853PubMedCrossRef De Vita S, Quartuccio L, Isola M, Mazzaro C, Scaini P, Lenzi M et al (2012) A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis. Arthritis Rheum 64(3):843–853PubMedCrossRef
55.
go back to reference Maritati F, Fenoglio R, Pillebout E, Emmi G, Urban ML, Rocco R et al (2018) Brief report: Rituximab for the treatment of adult-onset IgA vasculitis (Henoch-Schönlein). Arthritis Rheumatol 70(1):109–114PubMedCrossRef Maritati F, Fenoglio R, Pillebout E, Emmi G, Urban ML, Rocco R et al (2018) Brief report: Rituximab for the treatment of adult-onset IgA vasculitis (Henoch-Schönlein). Arthritis Rheumatol 70(1):109–114PubMedCrossRef
56.
go back to reference Martinez-Taboada VM, Blanco R, Garcia-Fuentes M, Rodriguez-Valverde V (1997) Clinical features and outcome of 95 patients with hypersensitivity vasculitis. Am J Med 102(2):186–191PubMedCrossRef Martinez-Taboada VM, Blanco R, Garcia-Fuentes M, Rodriguez-Valverde V (1997) Clinical features and outcome of 95 patients with hypersensitivity vasculitis. Am J Med 102(2):186–191PubMedCrossRef
Metadata
Title
Diagnosis and management of leukocytoclastic vasculitis
Authors
Paolo Fraticelli
Devis Benfaremo
Armando Gabrielli
Publication date
01-06-2021
Publisher
Springer International Publishing
Published in
Internal and Emergency Medicine / Issue 4/2021
Print ISSN: 1828-0447
Electronic ISSN: 1970-9366
DOI
https://doi.org/10.1007/s11739-021-02688-x

Other articles of this Issue 4/2021

Internal and Emergency Medicine 4/2021 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine